February 22 Biotech Update

A little bit of news since yesterday and I will focus on them but more broadly the sector seemed to struggle yesterday. It had been outperforming so a day of.

February 21 Biotech Update

Long weekend and a significant lack of news. I do not think there was an expectation of big news but sometimes these long weekends can surprise with a flurry of.

February 17 Biotech Update

Some news to talk about today in a couple stocks and one idea I want to float that has been ruminating in my mind. The sector continues to do well.

Dave Trading – March 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

February 15 Biotech Update

We have some additional news yesterday but nothing that is necessarily positive for the sector. It certainly rallied in the afternoon and I suspect there is enough juice left for.

February 14 Biotech Update

Some decent news this morning for the sector but not quite a robust reaction. Perhaps the sector needs to pause after its recent run or perhaps it will rally later.

February 13 Biotech Update

A relatively slow start to the week, so I will start off with perhaps the most (maybe only) meaningful fundamental news and then highlight another stock that is very likely.

February 10 Biotech Update

So I think we need to be prepared for some more backlash and bad press given the decision by Marathon to think it is business as usual. So far the.

February 8 Biotech Update

Certainly some news for the sector and not great news but it seems to be having limited impact on the broader sector. In other words, people seem to be seeing.

February 7 Biotech Update

The sector (and I guess you could argue the market in general) has been pretty dull the past couple of days. During the past year these periods of no news.

February 3 Biotech Update

I was correct in my prediction that I would need to take care of a sick child (and still need to do so today but have some more time). It.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 6

Proposed solution and conclusion Finally, I’d like to draw some conclusions and offer a different solution.  First of all, it is clear that the corporate tax structure is way too.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 5

Proposed Policy Actions to curtail inversions All policy actions taken so far have been attempts at adjusting the tax code to greatly discourage inversion, but falls short of eliminating the.

January 31 Biotech Update

We had some earnings but the real potential mover of the sector is the meeting this morning with Trump. The headlines are still early but it looks like a net.

January 30 Biotech Update

Volatility is the name of the game with the daily flow of disruptive executive orders coming out of Washington but despite this the VIX has been going down and the.

January 27 Biotech Update

We obviously got some news and price action but most of it is explainable and somewhat predictable. I will highlight some of the news and focus on the BMY report.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 4

The incentives to invert Now that we have determined that inversions are not in America’s best interest and that multinational corporations are now actively seeking to invert, we must critically.

January 25 Biotech Update

Tomorrow is our big earning day (will not be able to write tomorrow so look for an update on the news Friday) but today we at least had a positive.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 3

A brief history of corporate tax inversion In 1982, McDermott Inc., an industrial company making nuclear reactor parts for the US Navy as well as deepsea oil and gas production.

January 24 Biotech Update

Still a slow start to the week especially for an earnings week. I will highlight a couple biotech points and one non-biotech. In terms of the non-biotech, I am becoming.

Dave Trading – February 2017

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 2

Corporate Tax impact on the Economy It is well documented through economic circles that taxes skew relative prices by shifting the supply curve to the left in a standard supply-demand.

January 23 Biotech Update

There is not a lot of new news out this week but this is a week where earnings start, which could pick up the pace a little in terms of.

Dave-Trading Alert – CELG

I was still not exercised, but it looks like tonight our CELG options will be exercised. Monday, we will be selling the February $120 calls. We will have 200 CELG.

January 20th Biotech Update

We are getting some more offerings as is expected post JPM but they seem slower than usual. In any case, we have more large cap pharma news that is pretty.

Tax Inversions: Regulation Chasing Corporate Tax Loopholes Part 1

The following was a research project completed for my Economics of Regulation class about tax inversions, the implications, and proposed solutions.  Since this is a large paper, it will be.

January 18 Biotech Update

We have some news to talk about that seems to be a net neutral but in terms of individual stocks are likely meaningful. I also do not want to beat.

January 17 Biotech Update

The sector appears to have shrugged off (relatively speaking as to what could have happened) the recent Trump noise on the industry and likely for good reason. It is only.

January 13 Biotech Update

JPM is over and I am back. It is a lot to digest, so I will do some broad highlights today and then get more into details on Monday. To.

January 9 Biotech Update

I am getting ready to head out to JPM but I wanted to have a quick JPM note this morning. In general, the news has been a little slow as.

January 6 Biotech Update

News continues to come in (both expected and unexpected) and the sector remains strong into JPM. Usually there is a tailwind JPM week that can last a little but eventually.

Browsing 31 / 3 articles